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Since February 2019, over 160  Chlamydia trachoma-
tis (CT) cases testing negative or equivocal by Aptima 
Combo 2 (AC2) but positive by Aptima CT test run with 
Panther instruments occurred in Finland. The AC2 test 
targets chlamydial 23S rRNA while the CT test targets 
16S rRNA. Sequencing of 10 strains revealed a nucleo-
tide substitution in 23S rRNA. The significance of this 
for the failure of the AC2 test to detect the variant is 
not yet known.
In mid-February, a discrepancy was noticed in test-
ing results for chlamydia in the Clinical Microbiology 
Laboratory of Turku University Hospital, Turku, Finland. 
A first-void urine (FVU) sample from a person in their 
30s had been referred for analysis with a multiplex 
sexually transmitted infection (STI) assay (Allplex STI 
Essential, Seegene, Seoul, Korea) and was clearly posi-
tive for  Chlamydia trachomatis  (cycle threshold, Ct 25; 
cutoff for positivity being ≤ 40). A urethral swab speci-
men taken on the same day was negative by Aptima 
Combo 2 (AC2) test run in the Panther Instrument 
(Hologic, San Diego, California (CA), United States 
(US)). The patient had visited the clinic for STI twice 
in January, and FVU samples on both visits had tested 
negative in the AC2 test. Moreover, this patient had a 
chlamydia-positive partner who was tested in another 
area of the country, where the Abbott m2000 test 
(Abbott Park, Illinois, US) is used for screening for 
chlamydia and gonorrhoea.
In the AC2 assay, chlamydial 23S rRNA and/or gono-
coccal 16S rRNA are amplified by transcription-medi-
ated amplification reaction (TMA), and DNA probes 
with chemiluminescent label are used to detect the 
amplicons. The results are given in relative light 
units (RLU). The amplification of  C. trachomatis  and 
gonococci can be distinguished by different kinetic 
profiles. The cutoffs given by the manufacturer are RLU 
25 for equivocal (RLU ≥ 25 – < 100) and 100 for a positive 
result (RLU ≥ 100) if only a chlamydial signal is detected. 
If both chlamydial and gonococcal signals are present 
or chlamydial result is indeterminate, the cutoff for C. 
trachomatis  equivocal is 85 RLU (RLU ≥ 85 – < 250). 
Samples with ≥ 250 RLU are positive for  C. trachoma-
tis, if both chlamydial and gonococcal signals are pre-
sent [1]. As the assay relies on automated equipment 
(Panther), when a given sample has been processed, 
the instrument flags the sample as negative, equivo-
cal or positive for chlamydia and/or gonococcus. 
While the manufacturer’s thresholds are accounted 
for during flagging, the instrument may also take into 
account other parameters so the results displayed by 
the instrument may not always reflect an interpretation 
strictly based on the RLU.
The FVU sample positive in Allplex was tested by AC2 
in duplicate and yielded RLUs 25 and 26, interpreted 
by the instrument as negative for both chlamydia and 
gonococcus. It was agreed that if there were other 
patients who had samples flagged negative for C. tra-
chomatis  despite of clinical suspicion, their samples 
should be tested also with the multiplex STI assay. 
During the next week, two such patients were detected 
(with Allplex test Cts 23 and 35 and AC2 RLUs 23 and 
28, respectively).
As soon as the discrepancy was observed, the distribu-
tor of the AC2 test (Immunodiagnostic, Hämeenlinna, 
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Finland) rapidly provided us with the Aptima CT (ACT) 
test kits. The ACT test targets chlamydial 16S rRNA and 
is recommended by US Centers for Disease Control 
and Prevention (CDC) guidelines for testing of  C. tra-
chomatis alone and/or for confirmation of the AC2 test 
results with an alternative gene target [2]. Since the 
vast majority of the samples in general yields RLUs < 10, 
we decided to retest all samples with RLU ≥10 with the 
ACT test since mid-February. The first three AC2 false 
negative samples (respectively from the three patients 
discussed above) were clearly positive with the ACT 
test with RLUs > 6,000 (cutoffs for low positive 100 and 
positive 5,000 [3]). During the first week of March, six 
more false-negative/equivocal patients by AC2 were 
found positive by ACT.
Case definition for false negative Chlamydia 
trachomatis and detected cases
A case was preliminarily defined as a person with an 
AC2-negative or equivocal sample yielding RLU in the 
range of 20–84 (with RLU < 25 being negative) and a 
positive result in the ACT test.
Between February and the end April 2019, a total of 26 
samples from 25 patients fulfilling these criteria were 
identified in Turku. Of these, 11 were male FVUs, 12 
female FVUs and two cervical swabs. The mean age of 
patients was 28 years (range: 17–48). Twenty-two sam-
ples were flagged in AC2 as negative for C. trachoma-
tis  and four as equivocal, three of the latter being 
requested new samples from patients whose samples 
had been flagged negative with RLUs 24–34 about 
4 weeks earlier. Eighteen of the 26 samples were also 
tested with Abbott m2000 that amplifies two targets in 
the cryptic plasmid. All except one were positive (the 
one sample with Ct 35 in Seegene Allplex test remained 
negative).
Prevalence of missed Chlamydia 
trachomatis cases in Southwest Finland
To assess the prevalence of AC2-negative or equivo-
cal (RLU 20–84)/ACT-positive samples in Turku area 
(hospital district of Southwest Finland), a total of 943 
samples sent for chlamydia testing with negative or 
equivocal result in the AC2 test were reanalysed by 
ACT. The percentage of ACT-positive results among the 
samples with various RLUs in the AC2 test is shown 
in Table 1.
Among all  C. trachomatis  positive samples by ACT 
or AC2 or both during the same period, 15% (15/98) 
were positive only with the ACT test, including one 
that was flagged as equivocal in AC2 test. Four of the 
AC2 negative (n = 3) or equivocal (n = 1)/ACT-positive 
samples were from patients who had been recalled for 
a control specimen because of a suspicious AC2 test 
results in early 2019. Without this known catch-up 
diagnostics the AC2-false negative samples would 
comprise 10% (10/98) of all chlamydia positives during 
those three weeks.
Samples referred for chlamydia-gonorrhoea screening 
are routinely not stored in Turku University laboratory. 
However, 17 samples (7 male and 6 female FVUs, as 
well as 2 vaginal and 2 cervical swabs) that had been 
sent for analysis with the previously used Anyplex 
STI-5 genitourinary panel and tested positive for one 
of those analytes (Mycoplasma genitalium,  M. homi-
nis, Ureaplasma urealyticum, U. parvum or Trichomonas 
vaginalis) were available. The samples were dated from 
June to December 2018. One male FVU sample taken in 
late June 2018 was AC2-negative (RLUs of aliquots 22 
and 19) but ACT-positive. The patient had previously 
given a FVU sample in mid-June and its RLU value in 
the original AC2 run was 31 and flagged as negative.
Since samples with RLUs in the range of 20–84 (AC2 
test) were almost always ACT-positive, their proportion 
Table 1
Samples negative or equivocal for Chlamydia trachomatis by Aptima Combo 2 retested by Aptima CT in Turku, Finland, 
11–29 March 2019 (n = 943)
Qualitative result in the original 
AC2 test according to the 
instrument display
RLU in the original AC2 
test
Number of samples 
tested by ACT test
Positive in the ACT 
n %
The AC2 test RLU 
values in the ACT 
positives
Negative or equivocal for CT 
and negative for GC
≤ 10 916 1 0.1 3
11–15 9 1 11 15
16–19 0 0 0 n.a.
20–84 15 13 87 20–49a
Negative for CT and positive 
for GC > 1,300 3 0 0 n.a.
AC2: Aptima Combo 2; ACT: Aptima CT; CT: Chlamydia trachomatis; GC: Neisseria gonorrhoeae; n.a.: not applicable; RLU: relative light units.
a One sample with RLU 49 was flagged as C. trachomatis equivocal; the others were reported as negative by the Panther instrument.
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of the studied samples was used as an approxima-
tion of the prevalence of AC2 negative or equivocal/
ACT positive cases. During the latter half of 2018, their 
average proportion was 0.4% (38/9,472) of all tested 
samples and 6% (38/624) of samples reported as posi-
tive for C. trachomatis by AC2.
Geographical distribution of cases
In addition to Turku University Hospital, the AC2 test 
is used in five other laboratories in Finland. HUSLAB, 
the largest clinical microbiology laboratory in Finland, 
serves the hospital district of Helsinki and Uusimaa 
and hospital district of Kymenlaakso. United Medix 
Laboratories Ltd and Synlab Finland Ltd provide chla-
mydia/gonorrhoea tests mainly for private sector cli-
ents and Finnish Student Health Service organisation 
operating in whole Finland but also for several cities 
in southern and western Finland. Furthermore, the 
AC2 test is used in local laboratories of the hospital 
districts of Satakunta and Päijät-Häme. Together these 
laboratories cover ca 50% of all chlamydia-gonorrhoea 
screening performed in Finland.
After the finding of AC2 negative or equivocal/ACT-
positive cases, the ACT test was introduced also in 
these laboratories to enable testing of samples giv-
ing RLU values above the background level in the AC2 
test as well as to make possible targeted retesting of 
e.g. samples collected in the STI clinics. The number 
of samples tested and the numbers of AC2- flagged 
negative or equivocal/ACT-positive samples in HUSLAB 
and United Medix Laboratories are presented in Tables 
2  and  3. In the local laboratories of Satakunta and 
Päijät-Häme hospital districts, seven and five ACT posi-
tive specimens with RLUs 20–40 and 13–25 in the origi-
nal AC2 test, respectively, have been detected. Synlab 
Finland Ltd has detected 13 cases. The location of the 
Table 2
Samples re-analysed with Aptima CT test in HUSLAB, Finland, 6 March–30 April 2019 (n = 757)
Qualitative result in the original AC2 test 
according to the instrument display
RLU in the original AC2 
test
Number of samples 
tested by ACT test
Positive in the ACT 
n %
The AC2 test RLU 
values in the ACT 
positives
Negative or equivocal for CT and negative 
for GC
≤ 10 330 2 0.6 5–7
11–15 266 7 2.6 14–15
16–19 71 13 18 16–19
20–84 73 68a 93 20–46
85–250 3 3b 100 89–97
Negative for CT and positive for GC 48–1,492 14 1 7.1 1,492
AC2: Aptima Combo 2; ACT: Aptima CT; CT: Chlamydia trachomatis; GC: Neisseria gonorrhoeae; RLU: relative light units.
a Of 50 samples ≥ 25 RLU, one sample was flagged as equivocal in the original AC2 test.
b Of three samples with RLU between 85 and 99, three samples were flagged as equivocal in the original AC2 test.
Table 3
Samples re-analysed with Aptima CT test in United Medix Laboratories Ltd, Finland, 1 March–7 May 2019 (n = 193)
RLU in the original AC2 test Number of samples tested by ACT Positive in the ACT n %
The AC2 test RLU values in 
the ACT positives
 ≤ 10 51 0 0 n.a.
11–15 101 2 2.0 13, 14
16–20 10 3 30 17, 18, 20
21–84 31a 31 100 21–33
85–250 0 0 0 n.a.
AC2: Aptima Combo 2; ACT: Aptima Chlamydia trachomatis; n.a.: not applicable; RLU: relative light units.
a All were flagged as negative by the Panther instrument.
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hospital districts where cases have been found and the 
number of cases in each district is shown in the Figure. 
Molecular analysis of cases
Respective samples from 10 cases, five originating 
from Turku and five from Helsinki area have been ana-
lysed at the University of Helsinki. Initial molecular 
characterisation (sequencing of 23S rRNA, 16S rRNA 
and typing based on momp gene) of the AC2 negative 
or equivocal (RLU 20–84)/ACT positive specimens show 
that all are genotype E, the most common genotype in 
Finland [4]. Compared with the reference sequence, C. 
trachomatis  E/Bour (HE601870.1), there is a single nt 
change in the chlamydial 23S rRNA gene in position 
1515 (C –> T) in the initially falsely negative or equivo-
cal specimens. Thus far, we analysed only a limited 
number of AC2 negative or equivocal/ACT positive 
samples (n = 10). The sequences have been deposited 
in GenBank (GenBank accession number MN006991*). 
They all contain the same change, whereas this change 
cannot be found in the C. trachomatis  reference strain 
sequences deposited in GenBank or in our previously 
sequenced  C. trachomatis  isolates [5] that had been 
AC2 positive.
Discussion
Previously, failure of  C. trachomatis  nucleic acid 
detection test or tests to detect a variant strain was 
reported from Sweden. The Swedish new variant of C. 
trachomatis  (nvCT) was first described in late 2006 
and detected when assessing the reason behind an 
unexpected 25% decrease in the number of chlamydia 
cases in Halland area on the western coast of Sweden 
[6]. The strain had a 377-bp deletion within its cryptic 
plasmid that included the only targets of Roche and 
Abbott CT/GC tests of that time. The individuals with 
false negative test results remained untreated and 
unintentionally spread the infection further. The fail-
ure of diagnostics had provided the nvCT with a selec-
tive advantage, so that by the time of its discovery, 
nvCt had gained a high proportion (up to 64%) of all 
chlamydia cases in some areas where it could spread 
undetected [7,8]. It was estimated that the variant had 
emerged in 2000–2002, i.e. the spread could have 
happened in about 5 years by introduction of the strain 
into high-frequency transmitting populations [8].
Thus far, we have not been able to confirm that the 
change detected in the 23S rDNA is the reason behind 
the current phenomenon, however it remains a likely 
explanation. Specific primers and probes are used in 
the target capture, TMA, and detection steps of theAC2 
assay. Even a single change in a suitable location 
could ruin performance of the test. The manufacturer 
has excluded erroneous function of the instruments 
and possibility of improperly functioning lots. A part 
of discrepant results may be due to higher sensitivity 
of single target detection in Aptima CT as compared 
with AC2 according to the performance data in the 
package inserts or lower sensitivity of the AC2 test in 
female FVU samples [1,3,9]. We do not know which of 
the patients (if any) detected thus far belong to same 
transmission chains. It is possible that strains with this 
change have been present in low numbers for a longer 
period of time.
Whatever the reason behind the false negative AC2 
test results, the finding of 6–10% more positives by an 
alternative test reminds us of the general principles in 
chlamydia testing: no single test detects all cases and 
the sensitivity of a given method vary according to the 
sample type. However, also the lessons learned from 
the Swedish variant are valid and worth a reminder 
[8]: a single target should not be trusted in molecular 
Figure
Numbers of detected AC2-negative or equivocal (RLU 
20–84)/ACT-positive cases in hospital districts of Finland, 















AC2: Aptima Combo 2; ACT: Aptima CT; HU: Helsinki and Uusimaa; 
KL: Kymenlaakso; PH: Päijät-Häme; RLU: relative light units; Sat: 
Satakunta; SW: Southwest Finland.
The number of cases found in each district figures for each district 
on the map. The districts in which both public and private 
laboratories use Aptima Combo 2 are indicated.
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diagnostics of infections. In our case the extended 
STI panel fortunately worked as a backup and it prob-
ably resulted in the discovery of the variant in an early 
phase of its spread. The first discrepant case was 
detected by an alert microbiologist trainee in report-
ing extended panel samples which are handled more 
manually than the chlamydia screening samples stud-
ied by the highly automated instrument with negative 
results sent directly to laboratory information system. 
Also, the close connection between laboratory and STI 
clinic played a crucial role in the rapid investigation of 
the discrepancy observed. The traditional quality indi-
cators of chlamydia tests include close follow-up of the 
percentage of positives, which has not decreased in 
our laboratories. However, manufacturers of molecular 
tests should develop algorithms to monitor events and 
trends in the data produced by their instrument, e.g. 
percentage of samples in the grey zone. The increased 
use of molecular systems and automated ‘black box 
automates’ challenges us to find new strategies to 
keep up with the microbial evolution and safeguard the 
continuous high quality of diagnostics.
*Addendum
The GenBank accession number was added on 04 June 2019.
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